VYLEESI (bremelanotide acetate)
HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT AGENTS · PREMENOPAUSAL ACQUIRED HYPOACTIVE SEXUAL DESIRE DISORDER
Cosette Pharmaceuticals
Drug class
HSDD Agents-Non-Selective Melanocortin Receptor Agonist
The term "HSDD Agents-Non-Selective Melanocortin Receptor Agonist" is an administrative and formulary classification rather than a broad, multi-drug therapeutic class. Read more about HSDD Agents-Non-Selective Melanocortin Receptor Agonist
1 drugs in this class 1 manufacturers
Drugs in HSDD Agents-Non-Selective Melanocortin Receptor Agonist
Filter & compare in the drug finder →
Opens the drug finder with HSDD Agents-Non-Selective Melanocortin Receptor Agonist preselected. Add indication or manufacturer filters there.
The term "HSDD Agents-Non-Selective Melanocortin Receptor Agonist" is an administrative and formulary classification rather than a broad, multi-drug therapeutic class.
It designates central nervous system medications, primarily represented by bremelanotide, that bind non-selectively to multiple melanocortin receptor subtypes (most notably MC3R and MC4R) to modulate central pathways governing sexual motivation and desire.
Agents in this category are indicated specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
-
wellfleetrx.com
The term "HSDD Agents-Non-Selective Melanocortin Receptor Agonist" is an administrative and formulary classification rather than a broad, multi-drug therapeutic class
-
formularynavigator.com
The term "HSDD Agents-Non-Selective Melanocortin Receptor Agonist" is an administrative and formulary classification rather than a broad, multi-drug therapeutic class
-
proteuspeptides.com
It designates central nervous system medications, primarily represented by bremelanotide, that bind non-selectively to multiple melanocortin receptor subtypes (most notably MC3R and MC4R) to modulate central pathways governing sexual motivation and desire
-
nih.gov
It designates central nervous system medications, primarily represented by bremelanotide, that bind non-selectively to multiple melanocortin receptor subtypes (most notably MC3R and MC4R) to modulate central pathways governing sexual motivation and desire
-
cetaf.org
Agents in this category are indicated specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
-
medlineplus.gov
Agents in this category are indicated specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.